CellCentric secures investment from American Cancer Society's impact venture capital fund to advance inobrodib, its ground-breaking p300/CBP targeted therapy

/PRNewswire/ -- CellCentric, a clinical stage, private biotechnology company pioneering small molecule inhibition of p300/CBP to treat cancer, today announces...

Related Keywords

United States ,Cambridge ,Cambridgeshire ,United Kingdom ,Morningside ,North Lanarkshire ,American ,Alice Pomponio ,Prnewswire Cellcentric ,Jason Dinges ,International Name ,Morningside Investments ,American Cancer Society Brightedge ,Morningside Technology Advisory ,American Cancer Society ,World Health Organisation ,American Cancer ,Androgen Receptor ,International Non Proprietary Name ,Managing Director ,Cellcentric Board ,Chief Executive Officer ,Cellcentric ,